Physician profile
Dara Hosch
NPI 1962550467
$624.34
in general payments reported to CMS, 2019-2025
12 companies · $96.59 in 2025
The $96.59 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $56.59 · 2023: $191 · 2024: $137 · 2025: $96.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $135.88 | 2020-2025 | |
| Ironshore Pharmaceuticals INC. | $127.35 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $61.47 | 2023-2025 | Doc Band |
| Sobi, INC | $59.76 | 2019-2020 | |
| Pfizer INC. | $47.37 | 2023-2025 | |
| Corium, LLC | $46.77 | 2023-2025 | Azstarys |
| Neos Therapeutics, LP | $45.67 | 2019-2023 | Adzenys Xr-Odt |
| Sanofi-Aventis U.S. LLC | $22.61 | 2025 | |
| Phadia US INC. | $21.70 | 2024 | Immunocap |
| Kaleo, INC. | $21.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.11 | 2023 | Flumist Quadrivalent |
| Shire North American Group INC | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Hosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.